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Obstructive sleep apnea is a sleep-related breathing disorder that has a major impact on
cardiovascular function. It has been associated with hypertension, coronary artery disease, cardiac arrhythmias, sudden cardiac death, and heart failure. This review focuses on
the relationship between obstructive sleep apnea and heart failure with either reduced or
preserved ejection fraction. We discuss the pathophysiology of obstructive sleep apnea,
as well as its prevalence, treatment outcomes with continuous positive airway pressure,
and prognosis in these 2 distinct types of heart failure. We also identify areas in which
further work is needed to improve our understanding of this association in heart failure
patients. (Tex Heart Inst J 2018;45(3):151-61)

H

eart failure (HF), which affects approximately 23 million people worldwide1
and 5.8 million in the United States, has created a substantial healthcare
burden.2 The incidence and prevalence of HF are increasing in the U.S.,
mainly because of an aging population and the ability to prolong cardiac patients’ lives
by means of innovative therapies.2 Many factors contribute to the development and
progression of HF; one of these is obstructive sleep apnea (OSA). The prevalence of
OSA is substantially higher in patients who have HF with reduced ejection fraction
(HFrEF) or HF with preserved ejection fraction (HFpEF) than in the general population. In this literature review, we explore the relationship between OSA and these 2
types of HF and provide perspective on the pathophysiologic and clinical significance
of these associations.
Sleep Apnea

Sleep apnea is characterized by partial or complete cessation of breathing during nighttime sleep, resulting in repeated arousal from sleep, oxyhemoglobin desaturation, and
daytime sleepiness. Apnea is defined as complete cessation of airf low for >10 s (Table
I).3 Hypopnea, a partial cessation of airf low, is defined as a 50% to 90% reduction
in airf low for >10 s, accompanied by a >3% decrease in oxyhemoglobin saturation
(Sao2) and terminated by electroencephalographic arousal.4 The 3 types of apnea
are central, obstructive, and mixed. Central sleep apnea (CSA) is characterized by a
complete withdrawal of central respiratory drive to the inspiratory muscles, including the diaphragm, and results in the simultaneous absence of naso-oral airf low and
thoracoabdominal excursions. In OSA, the thoracic inspiratory muscles, including the
diaphragm, are active, so thoracoabdominal excursions are seen. Absence of airf low
results from upper-airway occlusion caused by lost pharyngeal dilator muscle tone,
with consequent pharyngeal collapse. Mixed apnea has an initial central component
followed by an obstructive component. Like apnea, hypopnea can also be obstructive
or central. We focus here on obstructive causes.
Although OSA is also called obstructive sleep apnea-hypopnea syndrome,5 we use
the term OSA as defined by the American Academy of Sleep Medicine Task Force,
in which 5 or more episodes of apnea or hypopnea occur per hour of sleep (apneahypopnea index [AHI]). Clinically, OSA can present as daytime sleepiness or loud
snoring, witnessed apneas, arousal due to gasping or choking, impaired concentration
or memory, morning headaches, mood disorders, or insomnia.4 Obstructive sleep
apnea is classified as mild (AHI, 5–14), moderate (AHI, 15–30), or severe (AHI, >30).
Attended overnight polysomnography in a sleep laboratory is accepted as the best diagnostic test for measuring AHI. Portable cardiorespiratory monitoring devices have
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TABLE I. Terminology Used in Sleep-Disordered
Breathing3
Apnea
Cessation of airflow for >10 s
Hypopnea
A reduction in but not complete cessation of airflow to <50%
of normal, usually in association with a >3% reduction in
oxyhemoglobin saturation, lasting >10 s
Apnea-Hypopnea Index (AHI)
The frequency of apnea and hypopnea events per hour of sleep;
a measure of the severity of sleep apnea
Arousal
Transient awakening from sleep, lasting <10 s
Epworth Sleepiness Scale (ESS)
Subjectively measures sleepiness during routine daily activities
and is often used as a screening test for detecting excessive
sleepiness

population-prevalence estimates for mild and moderate
OSA range from 3% to 28% and 1% to 14%, respectively. On the basis of average prevalence, an estimated
1 in 5 adults has at least mild OSA and 1 in 15 has at
least moderate OSA.7 Data from the Sleep Heart Health
Study,15 in which investigators examined cross-sectional
relationships between sleep-related breathing disorders and self-reported cardiovascular disease in 6,424
adults, showed that OSA is associated with a 2.38 relative odds of having HF. The results of several studies
in HF populations show a diverse overall prevalence of
obstructive and central sleep-related breathing disorders
(range, 47%–81%), probably attributable to different
demographic criteria (age, sex, ethnicity, and race), risk
factors (obesity and comorbid conditions), AHI cutoff,
and severity of HF in the different populations.

NREM (non-rapid eye movement) sleep
Quiet sleep

Pathophysiologic Consequences of
Obstructive Sleep Apnea and Heart Failure

REM (rapid eye movement) sleep
Active sleep; associated with skeletal muscle atonia and
dreaming

Obstructive sleep apnea is characterized by recurrent
pharyngeal collapse during sleep. Patients generally have
a narrow, highly compliant pharynx that is prone to
collapse upon normal withdrawal of pharyngeal dilator
muscle tone during sleep, thus enabling airway narrowing (hypopnea) or occlusion (apnea). Many patients are
obese, and fat deposition around the pharynx may be
partly responsible for pharyngeal narrowing.16 Evidence
suggests that rostral displacement of fluid that has accumulated in the legs during the day causes edema of the
peripharyngeal structures when lying asleep, predisposing the individual to OSA.17-20
Obstructive sleep apnea is deleterious to the cardiovascular system through mechanical, chemical, neurohumoral, and inflammatory mechanisms (Fig. 1).21 The
immediate effects of an attempted inspiratory effort
during an episode of mechanical obstruction to airf low
include an exaggerated drop in intrathoracic pressure,
hypoxia, and arousal. The drop in intrathoracic pressure increases left ventricular (LV) transmural pressure,
which increases afterload; this drop in pressure increases
venous return, causing right ventricular distention and a
leftward shift of the interventricular septum and consequent decreased LV filling.22 The net result of decreased
LV filling and increased afterload is reduced stroke volume. Obstructive sleep apnea also causes marked and
repeated elevations in systemic blood pressure (BP) secondary to hypoxia, arousals from sleep, and increased
sympathetic nervous system activity (SNA). The SNA
is furthered by the decreased stroke volume, by suppression of the sympathetic inhibitory effects of lung
stretch receptors by apnea, or both. The combination of
increased LV afterload and faster heart rate secondary
to augmented SNA leads to myocardial oxygen supply/
demand mismatch, acutely predisposing the patient to
cardiac ischemia and arrhythmias, and chronically to
LV hypertrophy, LV enlargement, and HF.

Oxygen desaturation
Reduction in oxyhemoglobin saturation, usually consequent to
apnea or hypopnea
Polysomnography
Multiparametric electrophysiologic recording of
electroencephalographic, electroculographic, electromyographic,
electrocardiographic, and respiratory activity to identify sleeprelated breathing disturbances
Thoracoabdominal excursions
Measured qualitatively by respiratory inductance
plethysmography or by pneumatic respiration transducers
placed over the ribcage and abdomen
Adapted with permission from Chowdhury M, et al., J Card Fail
2010;16(2):164-74.3

also been developed for in-home screening and diagnosis of OSA. However, despite the advantages of convenience, lower cost, and patient acceptance, they measure
fewer physiologic variables than does polysomnography.
In-home polysomnographic results have not been meticulously validated and are not considered adequate to
guide therapy, particularly in the HF population.
Obstructive Sleep Apnea
in the General Population

In the general population, OSA affects approximately
4% of middle-aged men and 2% of middle-aged
women.6 The lower prevalence of OSA in women is
not well understood, although female hormones may
play a role.7,8 In the Wisconsin Sleep Cohort Study,6
a population-based prospective study of cardiopulmonary disorders of sleep in 3,513 participants, the
estimated prevalence of undiagnosed sleep apnea was
9% in women and 24% in men. In other studies,8-14
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Fig. 1 Diagram shows pathophysiologic mechanisms by which obstructive sleep apnea affects cardiovascular function and heart
failure. Modified with permission from Mann DL. Heart failure: a companion to Braunwald’s heart disease. Philadelphia: Elsevier; 2011.
p. 484.21
BP = blood pressure; HF = heart failure; HR = heart rate; LV = left ventricular; LVH = left ventricular hypertrophy; PNA = parasympathetic nervous system activity; RV = right ventricular; RVH = right ventricular hypertrophy; SNA = sympathetic nervous system activity;
SV = stroke volume; VR = venous return

Except for rapid-eye-movement (REM) sleep, which
generally constitutes 20% to 25% of sleep and is associated with short surges of sympathetic activity, sleep generally is a period of increased vagal activity that results
in slower heart rates and lower BPs. Conversely, arousals
after disordered breathing events in OSA increase SNA
and most likely the risk of HF development or progression.23
Hypoxemia with resultant systolic 24-28 or diastolic 29
dysfunction may also diminish oxygen delivery to the
myocardium. Risks include myocardial ischemia, arrhythmias, and sudden cardiac death during sleep
from the generation of free oxygen radicals and inflammation. Patients with OSA have low plasma nitrite
concentrations and diminished endothelial-mediated vasodilation.30 Reactive oxygen species selectively activate
inf lammatory pathways by activating nuclear factorkappa B (NFκB) rather than hypoxia-inducible factor-1
(HIF-1), the transcriptional regulator of the adaptive
pathway.31 Activation of NFkB leads to increased production of tumor necrosis factor-α, interleukin-6, interleukin-8, and C-reactive protein, as well as adhesion
molecules such as intracellular and vascular cell adhesion molecules, E selectin, and CD15,32 that can lead to
endothelial damage, atherogenesis, and HF. Infiltrating
Texas Heart Institute Journal

inf lammatory cells activate profibrotic transforming
growth factor-β, which leads to increased deposition of
extracellular matrix and consequent myocardial fibrosis,33 and to worsening LV diastolic function.
Prevalence of Obstructive Sleep Apnea in
Heart Failure with Reduced Ejection Fraction

Polysomnographic 34-39 and polygraphic study results40-42
have shown a higher prevalence of sleep-disordered
breathing (SDB) (47%–81%) and OSA (12%–53%)
in HFrEF patients than in the general population (Fig.
2).43 Table II34-42 summarizes prevalence studies of OSA
in HFrEF patients3; most patients were male, and mean
ages were similar. Mean body mass index (BMI) was
below 30 in all studies. The inclusion criteria varied
from AHI ≥5 to ≥15, and did or did not include patients
with CSA. The relative proportion of patients with
OSA or CSA tended to be highest in the studies that
categorized patients as having OSA at AHI ≥5; regardless, significant OSA is prevalent in HFrEF patients.
Older age,34,35,39-42 male sex,34 higher BMI,34,36-38 and
habitual snoring 36,38 are major risk factors for OSA in
patients with HFrEF, just as in the general population.6
However, OSA patients with HFrEF have less subjective
daytime sleepiness despite shorter sleep times, and the
Obstructive Sleep Apnea in Heart Failure
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Epworth Sleepiness Scale (ESS) is not helpful in identifying OSA in this population.34,39,44 Moreover, atrial
fibrillation,34,36-40,42 ventricular arrhythmias,36,38 lower
LV ejection fraction (LVEF),36,38,39,42 and higher levels
of serum brain natriuretic peptide (BNP),35,41 endothelin-1,35 and urinary norepinephrine39 have been reported
as predictors of risk for SDB and particularly CSA in
HFrEF.

60
53
49

Prevalence of OSA (%)

50
43
40

36
32

30

26

20

15

12

10

0

Yumino

Vazir

Javaheri

Sin

Ferrier

AHI ≥15/hr

Schulz

AHI ≥10/hr

Oldenburg Herrscher

AHI ≥5/hr

Fig. 2 Graph shows prevalence of obstructive sleep apnea
(OSA) in studies of patients with heart failure and reduced ejection fraction. Authors used Apnea-Hypopnea Index (AHI) cutoffs
of ≥15 events/hr (Yumino D, et al.34; Vazir A,* et al.35; Javaheri
S, et al.36; and Sin DD, et al.37), ≥10 events/hr (Ferrier K, et al.40;
and Schulz R, et al.39), and ≥5 events/hr (Herrscher T, et al.41; and
Oldenburg O, et al.42). Unattended overnight cardiorespiratory
polygraphy was used in hospital 39,42 and home 41 sleep studies;
otherwise, overnight-attended polysomnography was used. One
study was retrospective 37; the others were prospective. Because
of patient overlap between 2 studies,36,38 one 38 is not included
here.
Figure adapted with permission from Kasai T, Bradley TD. J Am
Coll Cardiol 2011;57(2):119-27.43
*Vazir A, et al.35 inconsistently refer to >15 and ≥15 AHI cutoffs.

Prevalence of Obstructive Sleep Apnea in
Heart Failure with Preserved Ejection Fraction

The prevalence of diastolic dysfunction has been studied echocardiographically in OSA patients who have no
history of HF (Table III).45-47 Fung and colleagues45 used
transmitral valve pulsed-wave Doppler echocardiography to find diastolic dysfunction (grade I) in 37% of
patients with newly diagnosed OSA. When comparing
patients with an AHI >40 versus <40, the authors reported an association between severe SDB and a higher
degree of diastolic dysfunction evidenced by prolonged
isovolumetric relaxation time (IVRT), although, of
note, this AHI cutpoint of 40 identified severely affected patients. Other authors reported abnormal diastolic
function (with use of tissue-Doppler echocardiography)
and an increased left atrial volume index in obese but
otherwise healthy patients with OSA in comparison
with similarly obese patients without OSA.46 Finally,

TABLE II. Prevalence Studies of Sleep-Disordered Breathing in Patients with Heart Failure and
Reduced Ejection Fraction3

Reference
Javaheri S, et al.38 (1998)a
Sin DD, et al.37 (1999)
40

81

100

63

28

0.25

75

>15

I–III

450

85

60b

29b

0.27b

66

>15

41

Herrscher T, et al.

(2011)e

44b

11

40

II–IV

37.6 b

32

29

53

15

12

37
40

0.34

NR

>10

I–IV

NR

0.24b

69

>15

I–III

44b

80

64.5b

27

0.283

46

>5

II–IV

24.7 b

36

203

75

65.3

27.6

0.28

57

>10

II–III

34b

43

28

55

100

61

29.4

0.306

53

> or ≥15c

II

27 b

15

38

218

77

55.6

29.2

0.25d

40

>15

II–IV

NR

26

21

71

85

61.4

28.4

0.296

73

>5

II–IV

NR

49

32

700

Yumino D, et al.34 (2009)

CSA
(%)

28

Oldenburg O, et al.42 (2007)
Vazir A, et al.35 (2007)

OSA
(%)

65

77
100

(2007)

AHI in
SDB
Pts*

60.1

53

Schulz R, et al.

LVEF

AHI
NYHA
ICM (%) Cutoff* Class

31b

100

39

(2005)

Male
(%)

Javaheri S, et al.36 (2006)a

Ferrier K, et al.

Mean
Mean
BMI
Age (yr) (kg/m2)

Pts
(n)

AHI = Apnea-Hypopnea Index; BMI = body mass index; CSA = central sleep apnea; ICM = ischemic cardiomyopathy; LVEF = left
ventricular ejection fraction; NYHA = New York Heart Association; NR = not reported; OSA = obstructive sleep apnea; Pts = patients;
SDB = sleep-disordered breathing
*Events/hr
a Significant difference between patients with and without SDB.
b Overlap of patients between 2 trials.
c Source article variably states >15 and ≥15.
d Data exclude CSA patients.
e Data exclude patients with heart failure with preserved ejection fraction.

All studies were prospective except Sin DD, et al.37 (retrospective).
Table adapted from Chowdhury M, et al. J Card Fail 2010;16(2):164-74.3 Used with permission.
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diastolic dysfunction was more prevalent in moderateto-severe OSA than in mild or no OSA.47
Data on the prevalence of SDB in patients with
HFpEF are sparse (Table IV).41,48,49 Chan and colleagues 48 found significant SDB in 11 of 20 patients
and used prolonged deceleration time to show that
those with SDB had worse diastolic dysfunction. In a
study of 244 patients with HFpEF, Bitter and associates 49 estimated that 69% had SDB (40% had OSA
and 29% CSA). The proportion of patients with SDB,
particularly CSA, increased as did diastolic dysfunction,
suggesting that CSA acts as a marker of HFpEF severity, as in HFrEF.42 In addition, older age, worse New
York Heart Association (NYHA) functional class, obesity, and higher levels of N-terminal pro-BNP were associated with both types of SDB. Diabetes mellitus and

higher BMI were predictors of OSA. When Herrscher
and colleagues 41 studied a population similar to that
of Bitter and associates in terms of age, sex, NYHA
class, and the use of HF medications, the prevalence of
OSA was 64%. Higher BMI was significantly associated with OSA. However, in these studies,41,49 SDB was
evaluated by using unattended overnight cardiorespiratory polygraphy; only Chan and colleagues’ patients
underwent overnight-attended polysomnography.48
CPAP in Patients with Heart Failure and
Reduced Ejection Fraction

In a study of the effects of continuous positive airway
pressure (CPAP) in 8 patients with OSA and HFrEF,50
oxygen desaturation, systolic BP, heart rate, and intrathoracic pressure decreased during stage 2 non-REM

TABLE III. Prevalence Studies* of Diastolic Dysfunction in Patients with OSA and No History of Heart Failure
Reference

Pts
(n)

Male
(%)

Mean Age		
(yr)
Characteristics

BMI		
(kg/m2)
AHI**

Findings

68
90
48.1
Newly diagnosed OSA
28.5
≥5
Fung JW, et al.45
(2002)							
							
							

DD in 37% pts;
more severe OSA
associated with worse
DD (longer IVRT)

Sidana J, et al.47
20
30
45
Obese, pregastric bypass;
49 vs 48
<5
(2005)				
12 pts with and 8 without		
>5–14
				OSA		
≥15
							

Moderate-to-severe
OSA associated with
higher prevalence of
moderate-to-severe DD

Otto ME, et al.46
41
100
45
Obese; 23 pts with
33.7 vs 32.3
≥15 vs <5
(2007)				
and 18 without OSA			
							
							

Increased left atrial
volume index and
DD in OSA pts vs
non-OSA pts

AHI = Apnea-Hypopnea Index; BMI = body mass index; DD = diastolic dysfunction; IVRT = isovolumetric relaxation time;
OSA = obstructive sleep apnea; Pts = patients
*With use of echocardiography
**Events/hr

TABLE IV. Prevalence Studies of Sleep-Disordered Breathing in Patients with Heart Failure
and Preserved Ejection Fraction
BMI (kg/m2)

Pts
(n)

Male
(%)

Mean
Age
(yr)

Mean

OSA

No SDB

Chan J, et al.48
(1997)

20

65

65

28

29.1a

27.6

>0.50

>10

Bitter T, et al.49
(2009)

244

64

65

NR

29.3b

26.4

>0.55

44

71

62.8

30.4

32b

27.9

Reference

Herrscher T, et al.41
(2011)c

LVEF

0.517

NYHA
AHI
Functional
Cutoff*
Class

OSA
(%)

CSA
(%)

II–III

35

20

≥5

II–IV

40

29

>5

II–IV

64

18

AHI = Apnea-Hypopnea Index; BMI = body mass index; CSA = central sleep apnea; LVEF = left ventricular ejection fraction; NR = not
reported; NYHA = New York Heart Association; OSA = obstructive sleep apnea; Pts = patients; SDB = sleep-disordered breathing
*Events/hr
a Patients with SDB (includes OSA and CSA)
b OSA versus no SDB, P <0.05
c Data exclude patients with systolic heart failure.
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sleep. Nocturnal CPAP has also been shown to reduce
central sympathetic vasoconstrictor outf low51 and improve vagal modulation of the heart by increasing highfrequency heart rate variability.52
Investigators have conducted randomized clinical
investigations (Table V)43,53-56 into the effects of nocturnal CPAP in patients with HFrEF and OSA. In
a monthlong study of 24 patients, Kaneko and colleagues53 found significant reductions in AHI, number
of arousals per night, and daytime systolic BP and heart
rate in conjunction with a decrease in LV end-systolic
diameter and an 8.8% absolute increase in LVEF on
2-dimensional echocardiograms. This study had no placebo group; however, the same measurement in the untreated control group did not improve, which suggests
that a sustained reduction in LV afterload secondary to
CPAP therapy was the reason for improved LVEF in the
treated group. This study included equal numbers of patients with ischemic and nonischemic cardiomyopathy.
Previously, the same group of authors,57 in an uncontrolled study of 8 patients with OSA and nonischemic
dilated cardiomyopathy, reported a 12% increase in
LVEF after one month of CPAP therapy. Upon withdrawal of CPAP for one week, LVEF worsened, strongly
suggesting that CPAP had reversed OSA. Mansfield
and co-authors,54 in a randomized trial of 40 patients,
reported that 3 months of CPAP treatment resulted in
a significant absolute increase of 5% in LVEF. However, no decrease in BP was reported; the authors at-

tributed this result to optimal vasodilator therapy that
may have diminished the beneficial effects of CPAP
on BP. The improved LVEF was related to a decrease
in SNA, as evidenced by a 42% decrease in overnight
urinary norepinephrine levels.54 The modestly improved
LVEF, as compared with that reported by Kaneko
and colleagues,53 can be attributed to less severe OSA
(AHI, 26 vs 42) and higher baseline LVEF (0.35 vs
0.28). There were also significant reductions in AHI
and improvement in subjective sleepiness measured by
the ESS. Smith and associates,55 in a placebo-controlled
crossover trial of autotitrating CPAP in 23 patients
with HFrEF and OSA, reported modest improvement
in subjective sleepiness, but none in other subjective or
objective criteria of HF severity, including LVEF. This
was notable, because these patients had baseline LVEF
and OSA severity similar to Kaneko and colleagues’ patients.53 Autotitrating CPAP has reduced AHI and ESS
scores as has fixed CPAP; however, the relative efficacy
of auto-CPAP versus clinically titrated CPAP remains
unclear.58,59 Compliance with CPAP was poorer 55 (3.5
hr/night) than that reported by Kaneko53 (6.2 hr/night)
and Mansfield54 (5.6 hr/night), and its efficacy was not
tested by using follow-up polysomnography. Therefore,
lower compliance with CPAP and thus its poorer efficacy might explain the absence of cardiovascular benefits.
In a randomized, multicenter, placebo-controlled trial
of CPAP therapy in 45 OSA patients with HFrEF,56

TABLE V. Clinical Trials of Effects of CPAP Treatment in Patients with OSA and Heart Failure with Reduced Ejection
Fraction43

Reference

Study
Groups

Baseline
Changes with CPAP Use
Mean
Mean
Pts Age Male BMI Duration CPAP
SBP
(n)
(yr)
(n) (kg/m2)
(mo)
(avg. hr) AHI* LVEF ESS AHI* LVEF ESS (mmHg)

Kaneko Y,
et al.53 (2003)

Control
CPAP

12
12

55.2
55.9

10
11

32.3
30.4

—
1

—
6.2

45.2 0.285
37.1 0.25

5.7 –0.5 0.15 NA
6.8 –28.8a 0.88a NA

6
–10a

Mansfield DR,
et al.54 (2004)

Control
CPAP

21
19

57.5
57.2

18
19

34.6
33.5

—
3

—
5.6

26
25

0.336
0.376

8.8 –8.4 0.15 11
9.5 –21.1a 0.50a –3.1a

–6
1

Smith LA,
et al.55 (2007)

Sham ACPAP
ACPAP

23
—

61
—

20
—

31
—

—
1.5

—
3.5

36
—

0.29
—

10
—

Egea CJ,
et al.56 (2008)c

Sham CPAP
CPAP

25
20

64
63

23
19

30.5
31.7

—
3

—
NR

35
44

0.272
0.288

6.9
–7.3 –0.05 –1.7
8.6 –32.9a 0.22a –3.6

NA
—

0.10
0.10

–2
–3b

NA
NA
–1.6
0

ACPAP = auto-titrating continuous positive airway pressure; AHI = Apnea-Hypopnea Index; avg = average; BMI = body mass index;
CPAP = continuous positive airway pressure; ESS = Epworth Sleepiness Scale; LVEF = left ventricular ejection fraction; NA = not
available; NR = not reported; OSA = obstructive sleep apnea; Pts = patients; SBP = systolic blood pressure; SDB = sleep-disordered
breathing
*Events/hr
aP <0.01 for comparison between groups
bP <0.05 for comparison between groups
cInvestigators studied patients with SDB, including both OSA and CSA; data shown here, except for AHI, are for patients with OSA.

Studies were randomized clinical trials; one55 included double-crossover.
Adapted with permission from Kasai T, Bradley TD. J Am Coll Cardiol 2011;57(2):119-27.43
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LVEF improved by an absolute 2.2% in the treatment
group. Even greater improvement in patients with baseline LVEF >0.30 suggests that myocardial contractile
reserve is a marker of LVEF improvement. Follow-up
polysomnography proved the efficacy of CPAP by revealing significantly reduced AHI in patients who had
CSA and OSA.
Investigators in a nonrandomized trial of patients
with HFrEF 60 compared the effects of acute and chronic
CPAP therapy on LV systolic and diastolic functions
in 7 patients with OSA and 5 without OSA. Stroke
volume and LVEF were reduced in acute CPAP administration, whereas 7 weeks of chronic CPAP resulted in
improved stroke volume and an absolute increase of 5%
in LVEF. Neither therapy affected diastolic function or
LV filling pressures. The improved stroke volume and
LVEF from chronic CPAP therapy was directly related
to the systemic vascular resistance index. Similarly, in an
observational study to evaluate the effects of 6 months
of CPAP therapy on HFrEF and OSA, Ferrier and associates61 compared 19 patients treated with CPAP and
7 untreated patients. With CPAP therapy, improvement
occurred in LVEF (4.7% absolute increase), systolic BP,
and sleepiness, but not in exercise levels, BNP, or sympathetic activity as measured by urinary norepinephrine
levels and heart rate. The modest increase in LVEF as
compared with that found by Kaneko and colleagues53
was attributed to lower compliance with CPAP (4.2 vs
6.2 hr/night) and less severe baseline systolic dysfunction (mean LVEF, 0.35 vs 0.28).
On the basis of the observations in the randomized (Table V)43,53-56 and nonrandomized clinical trials
of CPAP treatment in OSA and HFrEF, we concur
with the conclusions of Kasai and co-authors 52 that
f ixed-pressure CPAP reduces sympathetic activity,50,53,54 BP,50,52,60 and ESS scores,54,55,61 and improves
LVEF.53,54,56,60,61 Improved quality of life was noted in
patients with baseline ESS scores >10,54 but not in those
with scores <10.56,61 Autotitrating CPAP failed to improve LVEF.52
CPAP in Patients with
Heart Failure with Preserved Ejection Fraction

Investigators have examined the effects of CPAP therapy on LV diastolic function in patients with OSA but
without HFpEF. In a randomized, placebo-controlled,
double-blinded crossover study,62 diastolic function
improved in these patients after 12 weeks of CPAP
therapy. Conventional echocardiography showed improved function through significantly reduced IVRT
and deceleration time as well as an increase in the ratio
of peak early filling velocity (E) to peak late filling velocity (A) of diastolic transmitral f low (E/A). Other
authors 63 compared 15 patients who had moderate-tosevere OSA and no comorbidities with normal obese
persons and reported significantly decreased diastolic
Texas Heart Institute Journal

BP and improved diastolic dysfunction (increased E/A
ratio, decreased IVRT) after 3 months of CPAP therapy. Cloward and colleagues 64 reported regression of
LV hypertrophy in 25 patients with severe OSA after
6 months of nasal CPAP therapy. In another study,65
although LVEF was conserved, the authors reported
significantly reduced LV wall thickness (interventricular septum and LV posterior wall) and improved global
function after 6 months of CPAP therapy in patients
with severe OSA. Shivalkar and associates66 studied patients with OSA and no concomitant cardiopulmonary
disease who had 6 months of CPAP therapy and found
that their symptoms, hemodynamic status, and ventricular structure and function significantly improved.
Diastolic velocities improved significantly in younger
patients and variably in older patients.66 In another
study,67 tissue-Doppler images showed improved systolic
and diastolic function after 6 months of CPAP therapy
in patients with newly diagnosed OSA.
We are unaware of randomized or nonrandomized
clinical trials of the effects of chronic CPAP therapy in
patients with OSA and HFpEF. The only report of diastolic function in patients with OSA and HFpEF after
CPAP therapy noted no changes in relevant echocardiographic indices.60 However, this study lasted only 7
weeks, so longer therapy may be necessary to determine
whether CPAP has beneficial effects on diastolic function, as reported in the studies of patients with OSA and
no history of HFpEF (3–6 mo).62-67
Effects of CPAP on Morbidity and Mortality
Rates in Heart Failure with Reduced Ejection
Fraction

In a study of HF patients undergoing evaluation for heart
transplantation, Roebuck and colleagues68 monitored 22
patients with OSA and 23 patients without OSA for a
median duration of 52 months. Results of CPAP’s efficacy were inconclusive, because no distinction was made
between treated and untreated OSA. Few investigators
have researched the effects of CPAP on mortality rates
in OSA patients with HFrEF (Table VI).69,70 Wang and
associates 69 prospectively recruited 164 patients with
HFrEF, categorized them into 3 groups (mild to no sleep
apnea, untreated OSA, and OSA treated with CPAP),
and monitored them for a median duration of >7 years.
After control for confounding variables, the mortality
rate was significantly higher among the group of 37 patients with untreated moderate-to-severe OSA than in
the group with mild to no sleep apnea. The 14 patients
treated with CPAP had slightly better survival prospects
than did the untreated patients (P=0.07). The study was
limited by small sample size, nonrandomization, higher
baseline AHI in the treatment group, and unavailable
data on CPAP compliance; a large-scale, randomized
trial might confirm better survival rates in HFrEF patients whose OSA is treated.
Obstructive Sleep Apnea in Heart Failure
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TABLE VI. Observational Studies of Effects of CPAP Treatment on Long-Term Outcomes in Patients with OSA and
Heart Failure with Reduced Ejection Fraction43

Design

Pts
(n)

Male Age BMI
(%)
(yr) (kg/m2) LVEF

Wang H, et al.69 M-NSA
(2007)
Untreated
Treated

113
37
14

66
87
100

23
65

83
95

Reference

Kasai T, et al.70
(2008)

Untreated
Treated

53.5 29
58.5 30.1
53.2 32.3*

AHI
CPAP Follow-Up
(events/ (avg. hr/ Mean/Max.
hr)
night)
(yr)

Findings

0.255
0.259
0.239

6.9
32.8
38.8

—
—
NR

2.9/7.3

Higher mortality rate in
untreated group vs M-NSA
group; tendency toward
decreased mortality rate in
treated vs untreated group
(P=0.07)

59.8 24.9
0.35
59.6 27.5** 0.362

38.2
45.1

—
4.9

2.1/4.8

Increased risk of death and
hospitalization in untreated
group (P=0.03) and less
compliant CPAP-treated group
(P=0.01)

AHI = Apnea-Hypopnea Index; avg = average; BMI = body mass index; CPAP = continuous positive airway pressure; LVEF = left
ventricular ejection fraction; Max. = maximum; M-NSA = mild to no sleep apnea; NR = not reported; OSA = obstructive sleep apnea;
Pts = patients
*P <0.05 for comparison with M-NSA
**P <0.05 for comparison between groups
Adapted with permission from Kasai T, Bradley TD. J Am Coll Cardiol 2011;57(2):119-27.43

Kasai and colleagues 70 classif ied 88 patients with
moderate-to-severe OSA into a CPAP-treated group
(n=65) and an untreated group (n=23). The CPAP
group was subdivided into 2 groups: more compliant (n=32; average nightly CPAP use, 6 hr) and less
compliant (n=33; average nightly CPAP use, 3.5 hr).
After a mean duration of 2.1 years, increased risk of
death and hospitalization was found in the untreated
(P=0.03) and less compliant (P=0.01) groups. Because
of the small sample size and the 39% first-month dropout rate among untreated patients, these findings need
to be confirmed by results from a larger study.
Jilek and co-authors,71 in an observational study of
273 patients with HFrEF, concluded that SDB was associated with higher mortality rates and positive airway
pressure was associated with improved prognosis. The
study compared mortality rates in patients with severe
SDB versus none to moderate SDB; however, only 22%
of patients in the severe-SDB group had predominant
OSA, so the results did not confirm that CPAP would
lower mortality rates in patients with HFrEF.
In an observational study of 384 patients with HFrEF
(62% had OSA), Damy and coworkers 72 reported a
poor prognosis after a mean follow-up period of 47 ±
25 months in patients whose OSA had improved with
use of nocturnal ventilation therapy (CPAP with bilevel
positive airway pressure and adaptive seroventilation).
Because of the nonrandomized nature of this study, the
cutoff of 20 events/hr for treatment, and the different
ventilation modes, we think that these findings need
confirmation by a larger and randomized trial in which
patients receive treatment on the basis of the most recent
recommendations. Khayat and colleagues, who had
suggested a role for OSA in acute decompensation of
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HF,73 later found that severe OSA (AHI, >30) independently predicted 6-month cardiac hospital readmissions
in patients with HFrEF. However, this does not show
that CPAP treatment would necessarily be effective.74
Remaining Questions and Challenges

We found no studies in which the effects of CPAP on
mortality rates in patients with OSA and HFpEF were
examined. Further research is needed.
Obstructive sleep apnea contributes substantially to
the development and progression of HF. In patients
with HFrEF and HFpEF, OSA is more prevalent than
in the general population. However, the effects of CPAP
on HF progression and mortality rates have been studied only in OSA patients who have HFrEF. Promising
echocardiographic studies have been conducted into
the effect of CPAP on diastolic dysfunction in patients
with OSA. In addition, despite considerable advances
in managing OSA in HFrEF, minimal progress has
been made in managing OSA in HFpEF. Therefore,
randomized clinical trials are certainly needed to evaluate the effects of CPAP on HF progression and survival
prospects in HFpEF patients with OSA.
Furthermore, excessive daytime sleepiness caused by
repeated arousals at night is characteristic of OSA in patients without HF. Patients with OSA and HF have less
subjective daytime sleepiness despite less sleep time, and
the ESS is unhelpful in predicting OSA in this population.34,39,41,44 Although fixed-pressure CPAP reduces ESS
scores in HFrEF patients,54,55,61 it improves quality of life
only when baseline ESS scores are >10.54
These observations illuminate 3 important questions regarding the relationship between OSA and HF.
First, which HF patients need a screening sleep study
June 2018, Vol. 45, No. 3

when the ESS is unreliable for screening? Schulz and
colleagues 40 recommended sleep studies in all HFrEF
patients with LVEF <0.40; however, this idea has not
been generally accepted, because of uncertainty about
whether and how to treat OSA in this population and
the need for treatment goals.75 Currently, because of no
guidelines, the indications for sleep studies to evaluate
OSA in patients without HF apply equally to patients
with HF: obesity, habitual snoring, witnessed apnea,
unrefreshing sleep, excessive daytime sleepiness, and
hypertension.
Second, subjective excessive daytime sleepiness may
be absent in patients with OSA and HF, so do they need
CPAP treatment? This question applies even to patients
with OSA and no evidence of HF. The observations by
Wang 69 and Kasai70 support CPAP in patients with HF,
regardless of daytime symptoms. However, the need for
large-scale, highly powered clinical trials is apparent.
Third, the ESS is unreliable in HF patients, so there
is a need for a new sleepiness scale that can better predict the risk of OSA in these patients. Poor quality of
life in HF might be why sleepiness is not perceived as a
predominant symptom; the new sleepiness scale should
take quality of life into consideration.
Because patients with HFpEF and OSA share clinical profiles, it may not be surprising if a large study
were to show that OSA is more prevalent in HFpEF
than in HFrEF, a finding noted in the only small-scale
study that included both HFpEF and HFrEF patients.41
For these reasons, we think that further elucidation of
the role of OSA and OSA treatment in patients with
HFpEF is needed.
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